Recommended lusutrombopag for tumor CTIT patients (Grade III recommendation, Category 2B evidence).

Patients with thrombocytopenia caused by chronic liver disease may use recombinant human thrombopoietin or thrombopoietin receptor agonists (such as avatrombopag, lusutrombopag) to increase platelet count according to clinical needs.

Recommendation 5: Lusutrombopag and avatrombopag are recommended for the treatment of perioperative thrombocytopenia in liver cancer patients. (Agreement rate: 100%)

Recommendation 7: For patients with mild to moderate renal or liver impairment, neither lusutrombopag nor avatrombopag requires dosage adjustment. Comprehensive assessment of potential therapeutic risks is required before administration in other special populations. (Agreement rate: 100%)

Recommendation 4: When cirrhotic patients with thrombocytopenia undergo invasive procedures, surgery, or anti-tumor drug therapy, recombinant human thrombopoietin (rhTPO) or thrombopoietin receptor agonists (TPO-RA) may be used according to the required platelet threshold to reduce bleeding risk. (C1)